Foderaro A E, Baird G L, Bazargan-Lari A, Morrissey P E, Gohh R Y, Poppas A, Klinger J R, Ventetuolo C E
Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island.
Department of Surgery, Brown University School of Public Health, Providence, Rhode Island.
Transplant Proc. 2017 Jul-Aug;49(6):1256-1261. doi: 10.1016/j.transproceed.2017.01.085.
Pulmonary hypertension in the setting of renal transplantation has been associated with early allograft dysfunction and increased mortality, but this relationship has not been extensively studied.
We performed a retrospective cohort study of adult patients who underwent their first renal transplantation in the years 2003-2009 and had pre-transplantation echocardiograms. Pulmonary hypertension was defined as right ventricular systolic pressure ≥40 mm Hg in the absence of left-sided valvular disease and/or left ventricular ejection fraction ≤50%. Eighty-two of 205 patients (40%) met the inclusion criteria. The relationship between pulmonary hypertension and death-censored allograft failure (hemodialysis dependence or retransplantation) and serum creatinine was assessed with the use of Cox hazard regression and generalized mixed models.
The presence of pulmonary hypertension was associated with a 3-fold increase in the risk of death-censored allograft failure (95% confidence interval, 1.20-7.32; P = .02). Failure rates were 19% at 24 months and 51% at 96 months for those with pulmonary hypertension versus 7% at 24 months and 20% at 86 months for those without pulmonary hypertension (P = .01). Among those without graft failure, there was an increase in creatinine levels after transplantation (P = .01). Effect estimates were unchanged by adjustment for multiple covariates and when pulmonary hypertension was defined as right ventricular systolic pressure ≥36 mm Hg.
Pulmonary hypertension before renal transplantation carries a 3-fold increased risk of death-censored allograft failure. The relationship between the pulmonary circulation and renal allograft failure warrants further study.
肾移植患者的肺动脉高压与移植肾早期功能障碍及死亡率增加相关,但这种关系尚未得到广泛研究。
我们对2003年至2009年期间接受首次肾移植且有移植前超声心动图检查的成年患者进行了一项回顾性队列研究。肺动脉高压定义为在无左侧瓣膜病和/或左心室射血分数≤50%的情况下右心室收缩压≥40 mmHg。205例患者中有82例(40%)符合纳入标准。使用Cox风险回归和广义混合模型评估肺动脉高压与死亡删失的移植肾失功(血液透析依赖或再次移植)及血清肌酐之间的关系。
肺动脉高压的存在与死亡删失的移植肾失功风险增加3倍相关(95%置信区间,1.20 - 7.32;P = .02)。有肺动脉高压者24个月时的失功发生率为19%,96个月时为51%,而无肺动脉高压者24个月时为7%,86个月时为20%(P = .01)。在未发生移植肾失功的患者中,移植后肌酐水平升高(P = .01)。在对多个协变量进行调整后以及将肺动脉高压定义为右心室收缩压≥36 mmHg时,效应估计值不变。
肾移植前的肺动脉高压使死亡删失的移植肾失功风险增加3倍。肺循环与移植肾失功之间的关系值得进一步研究。